HDM2 is a negative regulator of p53, a tumor suppressor protein that prevents uncontrolled cell division (Wang et al., 2023). Targeting HER2-positive and triple-negative subtypes will halt HDM2 overexpression correlates with poor prognosis leading to breast cancer treatment. Here, TP53 is linked to breast carcinoma.